Triple negative breast cancers are tipically associated with por prognosis, due to aggressive tumor phenotype(s), only partial response to chemoterapy and present lack of clinically established targeted therapies and respresent the focus of increasing interest at the clinical, biological and epidemiological level, as disclosed in Podo et al., Triple –negative breast cancer: Present challenges and new perspectives, Mol. Oncol., 2010, 4, 209-229.
There is, thus, a particular need for new active agents suitable for breast cancer treatment, and in particular need for triple negative breast cancers.
Description of the technology
The present invention relates to a new use of zonisamide, namely to zonisamide for use in the treatment breast cancer, in particular triple negative breast cancer tumours. It relates also to a pharmaceutical composition comprising zonisamide and at least one pharmaceutically acceptable excipient or vehicle, for use in the treatment of breast cancer.
Specifications
The zonisamide inhibits the LOXL2-enzymatic activity, and consequently opens a therapeutic window for the treatment of breast cancer, in particular triple negative breast cancer.
Main advantages of its use
Applications
IMIM (Hospital del Mar Medical Research Institute), located at the Barcelona Biomedical Research Park (PRBB) is, up to 82%, made up of research groups lead by professionals from the MAR Health Park , most of whom are associates of the Autonomous University of Barcelona (UAB) and the Pompeu Fabra University (UPF), as well as other seconded staff members from the Centre for Research in Environmental Epidemiology (CREAL), the Centre for Genomic Regulation (CRG), the Department of Experimental and Health Sciences of the Pompeu Fabra University (DCEXS-UPF), the Centre of Regenerative Medicine in Barcelona (CMRB) and the Barcelona Biomedical Research Park (PRBB).
On 16 December 2013, the Accreditation Committee of the Carlos III Health Institute (ISCIII) approved the acreditation of IMIM as a Health Research Institute, which was ratified by the State Secretarial of Research, Development and Innovation for the Order of 17 February 2014.
At IMIM there are around seven hundred professionals, of which one hundred and nineteen are lead researchers distributed in fifty-six research groups integrated into the five multi-disciplinary programmes framing research activities within IMIM:
Cancer, directed by Joan Albanell
Epidemiology and Public Health, directed by Jordi Alonso
Cardiovascular and inflammatory processes, directed by Miguel López-Botet
Biomedical Informatics, directed by Ferran Sanz
Neurosciences, directed by Rafael de la Torre
A large proportion of its budget is provided by external competitive funds that are managed by the Mar Institute of Medical Research Foundation.
The scientific output generate from this research includes almost 550 annual papers in international journals indexed in the Science Citation Index (SCI). Another relevant fact is that 65% of the IMIM papers are published in journals that are in the top quartile of their category.
IMIM has a Scientific Advisory Board (SAB) made up of a group of prestigious international expert scientists from the different areas of the IMIM research programmes.
Create your free account to connect with IMIM Institut Recerca Hospital del Mar and thousands of other innovative organizations and professionals worldwide
Send a request for information
to IMIM Institut Recerca Hospital del Mar
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
